

# A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study

Anand Kumar, MD; Nasia Safdar, MD; Shravan Kethireddy, MD; Dan Chateau, PhD

## LEARNING OBJECTIVES

After participating in this educational activity, the participant should be better able to:

1. Select antibiotic choices for treatment of patients with sepsis.
2. Evaluate efficacy of combination antibiotic therapy in patient with sepsis and septic shock.
3. Prescribe appropriate antibiotic regimens for critically ill patients with sepsis.

Unless otherwise noted below, each faculty or staff's spouse/life partner (if any) has nothing to disclose.

Dr. Kumar has disclosed that he was a recipient of grant/research fees from Lilly, Pfizer, Merck, Astellas, Astra-Zeneca, Roche, Ortho, Johnson & Johnson, and Bayer; was a consultant/advisor for Lilly, Pfizer, Merck, Astellas, Astra-Zeneca, and Roche; and is currently receiving grant/research fees from Roche and Astellas. The remaining authors have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.

All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationship with, or financial interests in, any commercial companies pertaining to this educational activity.

Visit the *Critical Care Medicine* Web site ([www.ccmjournal.org](http://www.ccmjournal.org)) for information on obtaining continuing medical education credit.

**Objective:** To assess whether a potential benefit with combination antibiotic therapy is restricted to the most critically ill subset of patients, particularly those with septic shock.

**Data Sources:** OVID MEDLINE (1950–October 2009), EMBASE (1980–October 2009), the Cochrane Central Register of Controlled Trials (to third quarter 2009), the ClinicalTrials.gov database, and the SCOPUS database.

**Study Selection:** Randomized or observational studies of antimicrobial therapy of serious bacterial infections potentially associated with sepsis or septic shock. Fifty studies met entry criteria.

**Data Extraction:** Study design, mortality/clinical response, and other variables were extracted independently by two reviewers. When possible, study datasets were split into mutually exclusive groups with and without shock or critical illness.

**Data Synthesis:** Although a pooled odds ratio indicated no overall mortality/clinical response benefit with combination therapy (odds ratio, 0.856; 95% confidence interval, 0.71–1.03;  $p = .0943$ ;  $I^2 = 45.1\%$ ), stratification of datasets by monotherapy mortality risk dem-

onstrated substantial benefit in the most severely ill subset (monotherapy risk of death  $>25\%$ ; odds ratio of death, 0.51; 95% confidence interval, 0.41–0.64;  $I^2 = 8.6\%$ ). Of those datasets that could be stratified by the presence of shock/critical illness, the more severely ill group consistently demonstrated increased efficacy of a combination therapy strategy (odds ratio, 0.49; 95% confidence interval, 0.35–0.70;  $p < .0001$ ;  $I^2 = 0\%$ ). An increased risk of death was found in low-risk patients (risk of death  $\leq 15\%$  in the monotherapy arm) exposed to combination therapy (odds ratio, 1.53; 95% confidence interval, 1.16–2.03;  $p = .003$ ;  $I^2 = 8.2\%$ ). Meta-regression indicated that efficacy of combination therapy was dependent only on the risk of death in the monotherapy group.

**Conclusion:** Combination antibiotic therapy improves survival and clinical response of high-risk, life-threatening infections, particularly those associated with septic shock but may be detrimental to low-risk patients. (Crit Care Med 2010; 38:1651–1664)

**KEY WORDS:** sepsis; septic shock; outcome; serious infection; combination therapy; infectious diseases; antibiotic; critically ill

Associate Professor of Medicine (AK), Medical Microbiology and Pharmacology/Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada; Attending ICU Physician (AK), Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada; Associate Professor (NS), School of Medicine & Public Health, Section of Infectious Diseases, University of Wisconsin, Madison, WI; Fellow (SK), Department of Critical Care Medicine, University of

Manitoba Health Sciences, Winnipeg, Manitoba, Canada; Research Scientist (DC), Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Dr. Kumar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Kethireddy and Kumar served as the reviewers. Dr.

Safdar performed the meta-analysis and Dr. Chateau performed the meta-regression.

For information regarding this article, E-mail: [akumar61@yahoo.com](mailto:akumar61@yahoo.com)

Copyright © 2010 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/CCM.0b013e3181e96b91

**A**t the conclusion of this CME activity, participants should be able to select appropriate antibiotic regimens for patients with sepsis. Combination antimicrobial therapy is commonly used for the treatment of sepsis and septic shock. The most accepted rationale for this approach is the generation of an increased spectrum of coverage, even though current antimicrobials possess extremely broad activity. Assuming the pathogenic organism is susceptible to one antibiotic, the incremental benefit of combination therapy is uncertain. Although some animal models (1–3) and clinical studies of infection, including endocarditis, Gram-negative bacteremia, and neutropenic infections (4–6), support such combination therapy, the potential clinical benefit in other severe infections associated with sepsis and septic shock has been questioned. Two separate meta-analyses have failed to demonstrate evidence of improvement of outcome with combination therapy in immunocompetent patients with sepsis and/or Gram-negative bacteremia (7, 8).

Meta-regression studies have found that efficacy of some medical therapies, including immunomodulatory therapy of sepsis, can be contingent on the underlying severity of illness and risk of death (9–12). A potential survival benefit with combination antimicrobial therapy may be similarly restricted to high-risk groups. A benefit in the most severely ill patients may be diluted or offset by less severely ill patients in whom no benefit exists or adverse effects of combination therapy dominate.

We report a meta-analysis/meta-regression study undertaken to determine whether combination antimicrobial therapy reduces mortality compared to monotherapy in patients with serious bacterial infections that can cause sepsis/septic shock. The specific hypothesis was that any beneficial effect of combination antimicrobial therapy on mortality of life-threatening infection is restricted to patients with septic shock or otherwise high-risk of death.

## MATERIALS AND METHODS

### Study Selection and Dataset Derivation

Both randomized and observational studies of antimicrobial therapy of serious bacterial infections potentially associated with sepsis and/or septic shock were included irrespective of causative organism, Gram stain characteristics, pres-

ence of bacteremia, or specific clinical infection (as long as the primary cause of mortality in the infection was typically sepsis/septic shock). Sufficient data to calculate an odds ratio (OR) between single vs. combination antibiotic therapy had to be provided. Combination therapy was defined as a combination of two or more antibiotics of different antimicrobial class and mechanism of action (for example, two of three of a  $\beta$ -lactam, an aminoglycoside, or fluoroquinolones). The causative organism was required or, in the case of randomized trials, expected to be sensitive to both antimicrobials. Mortality and infection-related mortality were the primary outcome measures, although “clinical failure” was acceptable when mortality was not provided. Studies published in any language were reviewed.

Excluded were noninferiority studies comparing fixed regimens of a superior primary agent vs. an inferior agent of the same class with a second agent of a different class (because of the intrinsic, structural bias in such studies), investigations of endocarditis or meningitis (because the primary mechanism of death in these conditions is rarely sepsis/septic shock), and trials restricted to neutropenic sepsis. Two independent reviewers performed the literature searches and identified relevant eligible studies. Final selection of studies was performed by consensus.

### Data Sources

Relevant human studies were identified from OVID MEDLINE (1950–October 2009). This search strategy was adapted to search EMBASE (1980–October 2009) and the Cochrane Central Register of Controlled Trials (to third quarter 2009). The ClinicalTrials.gov database, the SCOPUS database, SIGLE (System for Information on Gray Literature), and Google Scholar were also utilized to search for relevant studies. Search terms included “sepsis,” “septicemia,” “septic shock,” “severe sepsis,” “bacterial pneumonia,” “empyema,” “bacteremia,” “bloodstream infection,” “peritonitis,” “bowel perforation,” “pyelonephritis,” “urinary tract infection,” “ischemic bowel,” “bowel infarction,” “enterocolitis,” “celulitis,” “necrotizing fasciitis,” “cholangitis,” “cholecystitis,” “mediastinitis,” and “abscess.” These search terms were cross-referenced against “drug therapy, combination,” “antibiotic,” “monotherapy,” or “combination therapy.” References from relevant articles were reviewed to identify additional potentially eligible studies. Meeting abstracts of the Inter-science Conference on Antimicrobial Agents and Chemotherapy, the American Society of Microbiology, the Infectious Diseases Society of America, the European Congress of Clinical Microbiology and Infectious Diseases, the Society for Healthcare Epidemiology of America, and the Society of Critical Care Medicine were reviewed from 1990 to 2009.

### Data Extraction and Modification

Whenever possible, relevant subgroups were extracted from published data. As a priority, eligible datasets were split into two mutually exclusive groups of septic shock and nonseptic shock or, if necessary, critically ill and noncritically ill. When the published dataset did not include this information, the primary study author of relevant studies was contacted to request these data. When possible, the monotherapy group was limited to  $\beta$ -lactams and/or fluoroquinolones (as the primary agent), and the combination therapy group required the same primary agent as part of the combination (to maximize comparability between the groups). Because of long-standing concerns regarding inferior results with aminoglycoside monotherapy, in particular, in the most severely ill (13, 14), these cases were excluded when the dataset provided sufficient detail to allow extraction. Neutropenic, culture-negative, and atypical organism (mycoplasma, Legionella, viral) sepsis cases were also extracted when possible.

A standard form was used to extract pertinent data. Data were extracted by two independent reviewers. When analyzed data were extracted or modified from the original dataset, calculations were also performed independently by the two reviewers. Any disagreement between the two reviewers was resolved by consensus.

### Statistical Analysis

**Meta-Analysis.** Pooled ORs and 95% confidence intervals (CIs) were calculated for each dataset. Pooled estimates of the OR and 95% CI were obtained using the random-effects model of DerSimonian and Laird (15). Because most prospective clinical studies of severe sepsis inclusive of septic shock have yielded mortality risks of  $>25\%$  and studies of sepsis without shock have yielded mortality risks of  $<15\%$  (16–18), eligible datasets were stratified (on an *a priori* basis) into three corresponding monotherapy mortality/clinical failure rate groups of  $<15\%$ ,  $15\%$  to  $25\%$ , and  $>25\%$ .

An OR of  $<1$  signifies decreased mortality with combination therapy compared to monotherapy. Results were supported by application of fixed-effects models (15). The analyses were performed using StatsDirect Software (StatsDirect, Cheshire, UK). Testing for heterogeneity was performed using the  $I^2$  statistic (19). This statistic can be interpreted as the proportion of total variation across studies attributable to heterogeneity (min–max,  $0\%$ – $100\%$ ). A funnel plot of the log of the OR against the sample size was performed to assess for potential selection biases, including publication bias (20). Stratified subgroup analyses were also performed.




Figure 1. Study selection and dataset derivation.

**Meta-Regression.** Because the  $I^2$  statistic indicated significant heterogeneity among the entire collection of datasets, meta-regression was performed (21,22). Possible sources for heterogeneity including mortality rate in the reference (monotherapy) group were investigated.

To analyze the relationship between reference (monotherapy) mortality rate and the relative treatment effect, the log OR of death with combination therapy was plotted against the monotherapy mortality rate (x-axis) for each study. A linear meta-regression weighted to reflect the variance of the individual datasets was used to model the data. The mathematical model described the relationship between the log of the OR of death with combination therapy as a function of the mortality rate in the monotherapy arm. Supplemental meta-regressions were performed to examine the interactions of monotherapy mortality risk with major stratification groups. These analyses were performed using SAS PROC MIXED (v9.1.3; SAS Institute, Cary, NC).

## RESULTS

### Trial Characteristics

Fifty studies were found to be suitable for inclusion in this analysis (23–73) (Fig. 1). Of the 1534 studies identified for initial examination, 59 were determined to potentially fit inclusion criteria after screening of published abstracts. Subsequently, nine studies were excluded after review of the article (4, 74–81). Of the 50 remaining eligible studies (23–73), 12 had data that could be split into mutually exclusive groups with differing severity of illness (25–29, 34, 42, 46, 54–56,60). Subset data for eight of these studies could be found in the original publication (25, 26, 28, 29, 34, 54, 55, 60). The authors of four other published studies provided supplemental data from the origi-

nal publication to separately analyze shock/nonshock cases (27, 42, 46, 56). As a result, 62 distinct datasets were available for analysis (Fig. 1, Table 1).

Of the 12 split datasets, eight were split by presence or absence of shock (27, 28, 34, 42, 46, 54–56). The other four were split by a severity of illness scoring system (25, 26, 29, 60). In addition, 17 datasets were modified by extraction of cases of aminoglycoside monotherapy (24, 30, 36, 37, 41, 45, 49–52, 54, 62, 65, 70–73). Six studies and nine total datasets retained or potentially retained some cases of aminoglycoside monotherapy (29, 34, 38, 40, 60, 63). Of the former, two studies had aminoglycoside monotherapy in approximately half the cases (29, 34), with similar mortality outcome with aminoglycoside monotherapy and  $\beta$ -lactam monotherapy; another had a maximum of 15% of monotherapy with aminoglycosides (60), and frequency was undefined in one (63). The inclusion of aminoglycoside treatment as monotherapy was uncertain in two studies (38, 40). Four studies had culture negative and/or atypical organism cases extracted (25, 46, 59, 67). Three studies had cases of neutropenic sepsis extracted (53, 67, 72). Microbiological sensitivity of pathogens to antibacterials was confirmed in all included cases for all but 14 studies (19 datasets). In the remainder, it was inferred in at least some cases (24–28, 33, 35, 44, 46, 48, 51, 59, 63, 64). Twelve eligible studies (13 datasets) represented randomized, controlled trials (RCTs) (23, 33, 35, 39, 46, 48, 51, 53, 57–59, 62, 67). The remaining studies were either prospective observational or retrospective cohort investigations (Table 1).

Table 1 summarizes the characteristics of the datasets utilized in this analysis. The number of evaluable cases of life-threatening infection in the 50 eligible trials was 8504 patients (4553 monotherapy, 3951 combination therapy). Sample size among the different datasets ranged from 16 to 1111. Most studies primarily involved therapy with a  $\beta$ -lactam with or without an aminoglycoside, fluoroquinolone, or macrolide.

A Cook's D (influence diagnostic) test demonstrated that none of the datasets exceeds the critical value, i.e., none has a disproportionate impact on the results.

### Meta-Analyses

Meta-analysis of the 62 eligible datasets demonstrated an estimated pooled OR for death/clinical failure of 0.856 (95% CI, 0.713–1.027) for combination compared to monotherapy regimens ( $p = .094$ ) (Fig. 2). There was no evidence of a publication bias based on the Egger method ( $p = .275$ ). The shape of the funnel plot was symmetrical. However, there was statistically significant heterogeneity among the eligible datasets (Breslow-Day chi-square = 125.03;  $df = 61$ ;  $p < .0001$ ,  $I^2 = 45.1\%$ ).

In Figure 2, datasets are listed in sequential order of increasing monotherapy mortality/clinical failure rate. Although the pooled OR fails to demonstrate a significant advantage of combination therapy, there is a gradual trend of the individual OR positions switching from the right (favoring monotherapy) to the left (favoring combination therapy) as monotherapy mortality/clinical failure rate increases. Stratification of the dataset by monotherapy mortality/clinical failure rate confirms this observation. The pooled OR for datasets when the monotherapy mortality/clinical failure rate is  $<15\%$  significantly favors monotherapy (OR, 1.53; 95% CI, 1.16–2.03;  $p = .003$ ;  $I^2 = 8.2\%$ ). The pooled OR for monotherapy mortality/clinical failure rate of 15% to 25% indicates no difference in efficacy of monotherapy or combination therapy (OR, 1.05; 95% CI, 0.81–1.34;  $p = .7657$ ;  $I^2 = 30.7\%$ ). However, combination therapy demonstrates a significant advantage over monotherapy when the rate of death/clinical failure exceeds 25% (pooled OR, 0.54; 95% CI, 0.45–0.66;  $p < .0001$ ;  $I^2 = 0\%$ ). Stratification of datasets results in a marked decrease in heterogeneity in all stratified groups, suggesting that variations in mortality/



Table 1. Study mortality and characteristics

Study (reference)	Study Design	Monotherapy, Number of Deaths or Clinical Failure/Total (%)	Combination Therapy, Number of Deaths or Clinical Failure/Total (%)	Difference in Combination vs. Monotherapy Mortality/Clinical Failure (%)
Sculier et al 1982 (23)	RCT	0/10 (0)	1/10 (10.0)	10
Karnad et al 1985 (24)	RCS	0/4 (0)	18/47 (38.3)	38.2
Vazquez et al <sup>a</sup> 2005 (25)	RCS	2/45 (4.4)	6/142 (4.2)	-0.2
Dwyer et al <sup>a</sup> 2006 (26)	POS	9/195 (4.6)	7/57 (12.3)	7.7
Baddour et al <sup>a,c</sup> 2004 (27)	POS	17/279 (6.1)	7/63 (11.1)	5
Rodriguez et al <sup>a</sup> 2007 (28)	POS	4/63 (6.3)	14/196 (7.1)	0.8
Chow et al <sup>a</sup> 1991 (29)	POS	3/42 (7.1)	2/34 (5.9)	-1.3
Kim et al 2003 (30)	RCS	8/90 (8.9)	6/24 (25.0)	16.1
Chokshi et al 2007 (31)	RCS	4/42 (9.5)	12/66 (18.2)	8.7
Martinez et al 2003 (32)	RCS	17/171 (9.9)	18/238 (7.6)	-2.4
Damas et al 2006 (33)	RCT	2/20 (10.0)	8/39 (20.5)	10.5
Korvick et al <sup>a</sup> 1992 (34)	POS	11/92 (12.0)	13/83 (15.7)	3.7
Cometta et al 1994 (35)	RCT	18/142 (12.7)	13/138 (9.4)	-3.3
Kreger et al 1980 (36)	RCS	8/60 (13.3)	35/140 (25.0)	11.7
McCue et al 1985 (37)	RCS	19/141 (13.5)	20/81 (24.7)	11.2
Bouza et al 1987 (38)	RCS	3/21 (14.3)	2/5 (40.0)	25.7
Carbon et al 1987 (39)	RCT	4/25 (16.0)	5/22 (22.7)	6.7
McCue et al 1987 (40)	RCS	30/185 (16.2)	21/80 (26.3)	10
Kuikka et al 1997 (41)	RCS	35/211 (16.6)	5/68 (7.4)	-9.2
Harbarth et al <sup>b,c</sup> 2005 (42)	RCS	1/6 (16.7)	6/20 (30.0)	13.3
Siegman-Igra et al 1998 (43)	RCS	7/42 (16.7)	7/15 (46.7)	30
Gullberg et al 1989 (44)	RCS	3/18 (16.7)	8/38 (21.1)	4.4
Leibovici et al 1997 (45)	POS	134/789 (17.0)	57/322 (17.7)	0.7
Heyland et al <sup>a,c</sup> 2008 (46)	RCT	13/76 (17.1)	21/75 (28.0)	10.9
Waterer et al 2001 (47)	RCS	18/99 (18.2)	11/126 (8.7)	-9.5
Dupont et al 2000 (48)	RCT	21/111 (18.9)	24/116 (20.7)	1.8
Patterson et al 2003 (49)	POS	9/47 (19.1)	1/15 (6.7)	-12.5
Kim et al 2002 (50)	RCS	12/59 (20.3)	11/42 (26.2)	5.9
Harbarth et al <sup>a,c</sup> 2005 (42)	RCS	4/19 (21.1)	10/62 (16.1)	-4.9
Fernandez-Guerrero et al 1991 (51)	RCT	58/275 (21.1)	21/91 (23.1)	2
Kuikka et al 1998 (52)	RCS	7/32 (21.9)	11/41 (26.8)	4.9
Piccart et al 1984 (53)	RCT	5/22 (22.7)	5/26 (19.2)	-3.5
Bodey et al <sup>a</sup> 1985 (54)	RCS	18/78 (23.1)	16/104 (15.4)	-7.7
Garnacho-Montero et al <sup>a</sup> 2007 (55)	RCS	7/29 (24.1)	7/46 (15.2)	-8.9
Vazquez et al <sup>b</sup> 2005 (56)	RCS	4/15 (26.7)	5/53 (9.4)	-17.2
Chamot et al <sup>a,c</sup> 2003 (57)	RCS	12/44 (27.3)	8/37 (21.6)	-5.7
Kljucar et al 1990 (58)	RCT	14/50 (28.0)	10/50 (20.0)	-8
D'Antonio et al 1992 (59)	RCT	17/60 (28.3)	7/32 (21.9)	-6.5
Hilf et al <sup>a</sup> 1989 (60)	POS	9/31 (29.0)	20/106 (18.9)	-10.2
Watanakunkorn et al 1993 (61)	RCS	17/58 (29.3)	10/38 (26.3)	-3
Klatersky et al 1973 (62)	RCT	7/22 (31.8)	3/23 (13.0)	-18.8
Montgomerie et al 1980 (63)	RCS	9/28 (32.1)	0/3 (0)	-32.1
Graninger et al 1992 (64)	RCS	10/31 (32.3)	4/14 (28.6)	-3.7
Baddour et al <sup>b,c</sup> 2004 (27)	POS	11/33 (33.3)	4/36 (11.1)	-22.2
Ko et al 2000 (65)	RCS	13/33 (39.4)	3/26 (11.5)	-27.9
Aspa et al 2006 (66)	POS	99/251 (39.4)	61/198 (30.8)	-8.6
Fainstein et al 1983 (67)	RCT	13/32 (40.6)	10/39 (25.6)	-15
Maki et al 1988 (68)	RCS	14/34 (41.2)	18/46 (39.1)	-2
Dwyer et al <sup>b</sup> 2006 (26)	POS	11/25 (44.0)	3/8 (37.5)	-6.5
Mendelson et al 1994 (69)	RCS	4/9 (44.4)	4/15 (26.7)	-17.8
Garnacho-Montero et al <sup>b</sup> 2007 (55)	RCS	11/24 (45.8)	23/44 (52.3)	6.4
Heyland et al <sup>b,c</sup> 2008 (46)	RCT	12/24 (50.0)	5/17 (29.4)	-20.6
Chow et al <sup>b</sup> 1991 (29)	POS	6/12 (50.0)	8/30 (26.7)	-23.3
Korvick et al <sup>b</sup> 1992 (34)	POS	13/26 (50.0)	7/29 (24.1)	-25.9
Bodey et al 1989 (70)	RCS	39/72 (54.2)	16/76 (21.1)	-33.1
Rodriguez et al <sup>b</sup> 2007 (28)	POS	30/52 (57.7)	100/218 (45.9)	-11.8
Feldman et al 1990 (71)	RCS	5/7 (71.4)	0/9 (0)	-71.4
Bodey et al <sup>b</sup> 1985 (54)	RCS	9/12 (75.0)	28/52 (53.8)	-21.2
Chamot et al <sup>b,c</sup> 2003 (56)	RCS	9/11 (81.8)	4/6 (66.7)	-15.2
Hilf et al <sup>b</sup> 1989 (60)	POS	11/12 (91.7)	18/37 (48.6)	-43
Tapper et al 1974 (72)	RCS	1/1 (100)	13/20 (65.0)	-35
Hammond et al 1990 (73)	RCS	4/4 (100)	12/17 (70.6)	-29.4

CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; AG, aminoglycoside; FQ, fluoroquinolones; ESBL, extended-spectrum  $\beta$ -lactamase; RCT, randomized controlled trial; RCS, retrospective cohort study; POS, prospective observational study.

<sup>a</sup>Nonshock or shock or noncritically ill stratified dataset; <sup>b</sup> Shock or critically ill stratified dataset; <sup>c</sup> Modified dataset provided by study authors.

Table 1. —Continued

End Point	Clinical Infection	Antimicrobial Regimens	Septic Shock (%)	Neutropenic (%)
Infection-related hospital mortality	Gram-negative pneumonia	Mezlocillin ± sisomycin		
7-day mortality	Gram-negative pneumonia	β-lactam ± amikacin		6
Hospital mortality	Pneumococcal CAP	β-lactam ± macrolide		0
Hospital mortality	Bacteremic pneumococcal CAP	β-lactam ± macrolide		
14-day mortality	Pneumococcal bacteremia	Mixed combinations	0	
28-day mortality	Mixed organism CAP	Mixed combinations (β-lactam dominant as primary agent; FQ/macrolide as secondary)	0	
14-day mortality	Enterobacter bacteremia	β-lactam and/or AG	33	6
14-day mortality	Citrobacter/Serratia/Enterobacter bacteremia	β-lactam/FQ ± FQ/AG	17.3	14
Hospital mortality	Bacteremic pneumococcal CAP	β-lactam or FQ vs. lactam/FQ/macrolide combination	8.3	
Hospital mortality	Bacteremic pneumococcal CAP	β-lactam ± macrolide	9.8	4
28-day mortality	Mixed organism VAP	β-lactam ± AG/levofloxacin		
14-day mortality	Klebsiella bacteremia	β-lactam and/or AG	0	
Hospital mortality	Mixed organism sepsis	Imipenem ± netilmicin		0
7-day mortality	Gram-negative bacteremia	β-lactam ± AG		10
Hospital mortality	Gram-negative bacteremia	β-lactam ± AG		
Mortality after 7 days after of treatment	Serratia bacteremia	Mixed undefined combinations	28	
Hospital mortality	Gram-negative bacteremia	Cefotaxime ± amikacin	15	0
Hospital mortality	Gram-negative bacteremia	Mixed undefined combinations		7
30-day mortality	Escherichia coli bacteremia	Primarily β-lactam ± AG	22	13
30-day mortality	Pneumococcal sepsis	Mixed combinations (β-lactam dominant as primary agent; FQ/macrolide as secondary)	100	0
Infection-related hospital mortality	Pseudomonas aeruginosa bacteremia	Imipenem/cephalosporin/FQ ± AG		6
Hospital mortality	Enterococcal bacteremia	β-lactam/vancomycin ± AG		5
Hospital mortality	Gram-negative bacteremia	β-lactam ± AG	10.2	<10
28-day mortality	Gram-negative VAP	meropenem ± ciprofloxacin	0	0
15-day mortality	Bacteremic pneumococcal CAP	Primarily β-lactam or FQ vs. lactam/FQ/macrolide combination		
Clinical failure, 30 days after treatment	Mixed peritoneal sepsis/peritonitis	Piperacillin/tazobactam ± amikacin		
14-day mortality	ESBL Klebsiella bacteremia	Primarily β-lactam ± AG		<5
30-day mortality	Klebsiella bacteremia	β-lactam/FQ ± AG	18	
30-day mortality	Pneumococcal sepsis	Mixed combinations (β-lactam dominant as primary agent; FQ/macrolide as secondary)	0	0
Clinical failure, 2 days after treatment completion	Mixed organism hospital-acquired pneumonia	Cefotaxime ± mixed agents (primarily AG)		
30-day mortality	Pseudomonas aeruginosa bacteremia	β-lactam/ciprofloxacin ± AG (or ciprofloxacin for lactam)		28
Clinical failure or death during therapy	Gram-negative bacteremia	Cefoperazone ± amikacin		0
Clinical failure during therapy	Pseudomonas aeruginosa bacteremia	β-lactam ± AG	0	45
Hospital mortality	Pseudomonas aeruginosa VAP	β-lactam/FQ ± AG (or FQ for β-lactam)	0	
Hospital mortality	Pneumococcal CAP	β-lactam ± macrolide		0
30-day mortality	Pseudomonas aeruginosa bacteremia	β-lactam/FQ ± AG (or FQ for β-lactam)	0	30
Clinical failure, 7 days after treatment	Mixed organism hospital-acquired pneumonia	Ceftazidime ± tobramycin		
Clinical failure during therapy	Mixed sepsis	Ceftriaxone ± amikacin		0
10-day mortality	Pseudomonas aeruginosa bacteremia	β-lactam and/or AG		13.5
Hospital mortality	Enterococcal bacteremia	Penicillin drug/vancomycin ± gentamicin		
Infection-related hospital mortality	Gram-negative sepsis	Carbenicillin ± gentamicin	20	
Hospital mortality	Klebsiella bacteremia	β-lactam and/or AG		
21-day clinical failure or death	Enterococcal bacteremia	Ampicillin/piperacillin ± gentamicin/netilmicin		
14-day mortality	Pneumococcal bacteremia	Mixed combinations	100	
14-day mortality	Aeromonas bacteremia	β-lactam ± AG		
30-day mortality	Pneumococcal CAP	β-lactam ± macrolide	16	
Clinical failure during therapy	Mixed sepsis	Ceftazidime ± tobramycin	33	0
Hospital mortality	Enterococcal bacteremia	Ampicillin ± AG	19	
Hospital mortality	Bacteremic pneumococcal CAP	β-lactam ± macrolide		
Hospital mortality	Pseudomonas aeruginosa bacteremia	β-lactam ± AG		
Hospital mortality	Pseudomonas aeruginosa VAP	β-lactam/FQ ± AG (or FQ for β-lactam)	100	
28-day mortality	Gram-negative VAP	Meropenem ± ciprofloxacin	100	0
14-day mortality	Enterobacter bacteremia	β-lactam and/or AG	33	6
14-day mortality	Klebsiella bacteremia	β-lactam and/or AG	100	
Clinical failure during therapy	Klebsiella bacteremia	Cephalosporin ± AG	25	41
28-day mortality	Mixed organism CAP	Mixed combinations (β-lactam dominant as primary agent; FQ/macrolide as secondary)	100	
Hospital mortality	Klebsiella bacteremia	β-lactam/ciprofloxacin ± AG	12.8	
Clinical failure during therapy	Pseudomonas aeruginosa bacteremia	β-lactam ± AG	100	45
30-day mortality	Pseudomonas aeruginosa bacteremia	β-lactam/FQ ± AG (or FQ for β-lactam)	100	30
10-day mortality	Pseudomonas aeruginosa bacteremia	β-lactam and/or AG		13.5
Hospital mortality	Pseudomonas aeruginosa bacteremia	Carbenicillin ± gentamicin		0
Hospital mortality	Klebsiella CAP	Third-generation cephalosporin ± AG	83	




Figure 2. Analysis of studies comparing combination antibiotic therapy with monotherapy for reducing mortality of life-threatening infections associated with sepsis. Note the gradual shift of the odds ratio from the right to the left as monotherapy mortality increases. The size of the squares is proportional to the reciprocal of the variance of the studies. <sup>a</sup>, Nonshock or noncritically ill stratified dataset. <sup>b</sup>, Shock or critically ill stratified dataset. <sup>c</sup>, Modified dataset provided by study authors.

clinical failure risk represents a substantial portion of the heterogeneity in the aggregate meta-analysis. No other stratification resulted in a similar decrease of  $I^2$  in all strata (Table 2).

The 12 studies that were stratified into septic shock/critically ill and nonseptic shock/noncritically ill datasets were examined (Fig. 3). Pooled ORs for the eight studies split by the presence or absence of shock (27,28,34,42,46,54–56) and the

four studies split by the presence or absence of critical illness (25,26,29,60) demonstrated a significant advantage to combination therapy in the more ill group but did not demonstrate evidence of a similar trend in the less ill groups. Consolidation of the combined shock and critically ill datasets demonstrated similar results (OR, 0.51; 95% CI, 0.36–0.72;  $p = .0002$ ;  $I^2 = 0\%$ ). Pooled ORs for the consolidated nonshock/noncritically ill

show an absence of any beneficial effect with combination therapy (OR, 1.06; 95% CI, 0.76–1.47;  $p = .7178$ ;  $I^2 = 19.1\%$ ). Consolidation of all datasets yields a trend toward superiority of combination therapy that fails to reach significance (OR, 0.76; 95% CI, 0.57–1.02;  $p = .0622$ ;  $I^2 = 33.8\%$ ). The  $I^2$  value for study heterogeneity is substantially reduced by splitting the 12 datasets into shock/critically ill and nonshock/noncritically ill groups. As can be seen by examination of the datasets used in this analysis (25–29, 34, 42, 46, 54–56, 60) in Figure 2, the OR describing mortality/clinical failure with combination therapy for the septic shock or otherwise more critically ill subset of the individual datasets was shifted to the left (i.e., favoring combination therapy) relative to the matching nonseptic shock/noncritically ill dataset in 10 of the 12 datasets excluding only the studies of Harbarth et al (42) and Garnacho-Montero et al (55).

To further examine statistical heterogeneity in the aggregate meta-analysis and potential sources of variation in individual dataset results, additional stratified meta-analyses were performed (Table 2). Observational (non-RCT) studies (49 datasets) demonstrate a high level of heterogeneity and fail to show evidence of a benefit of combination therapy. A similar lack of evidence of efficacy is apparent whether examining prospective observational data (15 datasets) or retrospective cohort studies (34 datasets) (Tables 1 and 2). RCTs (13 datasets) demonstrate no significant benefit of a combination strategy despite low heterogeneity (Tables 1 and 2). Exploratory subgroup analyses to determine whether findings would differ by limiting the analysis to studies published during or before 1992 (29 datasets) or during or after 1993 (33 datasets), when more potent antimicrobials became available for serious infection demonstrated similar results (Tables 1 and 2).

Stratification by other criteria including use of  $\beta$ -lactam as sole primary therapy, aminoglycosides as the sole secondary agent, clinical syndrome (bacteremia, nonbacteremia, community-acquired pneumonia, hospital-acquired pneumonia/ventilator-associated pneumonia), Gram stain characteristic of pathogen, specific pathogen (*Pseudomonas*, *Klebsiella*, *Streptococcus pneumoniae*), and end point (hospital mortality, 7- to 30-day mortality, clinical failure) also showed no significant reduction in heterogeneity.

Table 2. Stratified summary values for meta-analyses and meta-regression

Stratification	Number of Datasets, Meta-Analysis	Meta-Analysis Pooled Random-Effects Odds Ratio (95% Confidence Interval)	Meta- Analysis <i>P</i>	<i>I</i> <sup>2</sup> , %	Number of Datasets, Meta-Regression	Meta-Regression Odds Ratio (95% Confidence Interval) Per 10% Increment of Reference Mortality <sup>a</sup>	Meta- Regression <i>P</i>
All datasets	62	0.856 (0.713–1.027)	.09	45.1	56	1.304 (1.205–1.412)	<.0001
Large datasets <sup>b</sup>	35	0.866 (0.706–1.062)	.17	52.9	35	1.213 (1.091–1.347)	<.0001
All split pair datasets	24	0.760 (0.568–1.018)	.07	34.3	24	1.185 (1.073–1.309)	.0028
Nonsplit pair datasets	38	0.919 (0.727–1.163)	.48	50.6	32	1.713 (1.530–1.918)	<.0001
Randomized	13	0.933 (0.720–1.224)	.61	1.7	12	1.425 (1.121–1.811)	.0159
controlled trials							
Non-randomized	49	0.840 (0.673–1.047)	.12	51.4	44	1.475 (1.385–1.569)	<.0001
controlled trials (observational studies)							
Prospective	15	0.772 (0.553–1.076)	.12	48.8	15	1.289 (1.162–1.430)	.0003
observational studies							
Retrospective cohort	34	0.883 (0.654–1.191)	.41	53.5	29	1.345 (1.177–1.537)	.0002
studies							
Clinical failure end	9	0.645 (0.430–0.950)	.02	47.8	9	1.364 (1.123–1.656)	.0166
point							
Hospital mortality end	24	1.136 (0.860–1.482)	.37	34.9	20	1.380 (1.232–1.546)	<.0001
point							
7-to 30-day mortality	29	0.774 (0.585–1.023)	.07	40.9	27	1.389 (1.229–1.568)	<.0001
end point							
Proven	43	0.805 (0.639–1.014)	.06	50.8	39	1.336 (1.212–1.473)	<.0001
microbiological							
sensitivity							
Inferred	19	0.984 (0.730–1.303)	.86	26.9	17	1.237 (1.078–1.419)	.0085
microbiological							
sensitivity							
During or after 1993	33	0.908 (0.728–1.132)	.39	40	33	1.286 (1.185–1.394)	<.0001
During or before 1992	29	0.774 (0.563–1.065)	.11	51.4	23	1.406 (1.252–1.579)	<.0001
Neutropenia in ≤10%	23	1.074 (0.824–1.400)	.59	30.7	20	1.288 (1.150–1.443)	.0002
of cases							
Neutropenia in >10%	11	0.570 (0.332–0.976)	.04	58.3	11	1.254 (1.135–1.386)	.0016
of cases							
β-lactam only as	32	0.840 (0.671–1.062)	.14	44.7	28	1.227 (1.121–1.343)	<.0001
primary Rx							
Mixed agents as	30	0.872 (0.647–1.175)	.36	47	28	1.310 (1.160–1.479)	.0002
primary Rx <sup>c</sup>							
AG excluded as	53	0.867 (0.717–1.049)	.14	43.8	48	1.397 (1.274–1.533)	<.0001
primary Rx							
AG only as secondary	29	0.824 (0.642–1.059)	.13	46.9	24	1.413 (1.246–1.604)	<.0001
Rx							
Non-AG as secondary	33	0.873 (0.661–1.152)	.33	45.6	32	1.268 (1.170–1.373)	<.0001
Rx <sup>d</sup>							
Macrolides only as	6	0.831 (0.503–1.372)	.47	40.8	6	1.077 (0.870–1.332)	.5335
secondary Rx							
Mixed agents as	25	0.877 (0.623–1.233)	.45	47.9	24	1.212 (1.104–1.330)	.0004
secondary Rx <sup>e</sup>							
Bacteremia	40	0.858 (0.660–1.116)	.25	56.6	37	1.391 (1.270–1.523)	<.0001
Nonbacteremia	22	0.820 (0.676–0.994)	.04	2.5	19	1.163 (1.016–1.331)	.0421
Community-acquired	11	0.780 (0.555–1.096)	.15	30.9	10	1.286 (1.087–1.521)	.0189
pneumonia							
Hospital-acquired	7	1.043 (0.704–1.546)	.83	17.9	7	1.302 (0.966–1.756)	.1440
pneumonia/ ventilator-associated pneumonia							
All pneumonia	18	0.870 (0.667–1.135)	.31	30.8	17	1.318 (1.143–1.519)	.0018
Gram-negative	37	0.829 (0.618–1.113)	.20	56.5	31	1.261 (1.145–1.388)	<.0001
infection							
Pseudomonas	12	0.747 (0.485–1.144)	.18	28.8	11	1.293 (1.119–1.495)	.0070
infection							
Klebsiella infection	8	0.441 (0.194–1.002)	.06	63.3	5	1.533 (1.218–1.930)	.0357
Gram-positive	17	0.830 (0.618–1.113)	.21	28.2	17	1.398 (1.169–1.672)	.0023
infection							



Table 2. —Continued

Stratification	Number of Datasets, Meta-Analysis	Meta-Analysis Pooled Random-Effects Odds Ratio (95% Confidence Interval)	Meta-Analysis <i>P</i>	<i>I</i> <sup>2</sup> , %	Number of Datasets, Meta-Regression	Meta-Regression Odds Ratio (95% Confidence Interval) Per 10% Increment of Reference Mortality <sup>d</sup>	Meta-Regression <i>P</i>
Pneumococcal infection	12	0.780 (0.605–1.063)	.06	47.3	12	1.413 (1.141–1.750)	.0088
Unmodified datasets	29	0.943 (0.736–1.208)	.64	32	27	1.381 (1.235–1.544)	<.0001
Modified datasets	33	0.777 (0.595–1.105)	.06	53.5	29	1.237 (1.140–1.341)	<.0001

Rx, therapy; AG, aminoglycoside.

<sup>a</sup>Change in log of the odds ratio of the probability of benefit with combination therapy with every 10% increase in mortality risk of the reference (monotherapy) group; <sup>b</sup>Datasets with an  $n \leq 25$  in either monotherapy or combination therapy arm excluded; <sup>c</sup>Primary agent other than  $\beta$ -lactam only (i.e., a mix of  $\beta$ -lactams and other antibiotics); <sup>d</sup>Secondary agent other than only aminoglycoside; <sup>e</sup>Secondary agents not specifically defined (may include aminoglycosides, fluoroquinolones, macrolides, or others). Note that number of datasets for meta-regression may be smaller than those used for meta-analysis because of the fact that meta-regression did not include studies when the estimate effect was infinite (i.e., 0% or 100% mortality in either arm).




Figure 3. Subset analysis comparing combination antibiotic therapy with monotherapy for reducing mortality of life-threatening infections associated with sepsis in shock/critically ill and nonshock/noncritically ill patient datasets (derived from 12 studies in which groups could be separated; see Table 1).




Figure 4. Meta-regression of all datasets. The weighted meta-regression line (with 95% confidence interval) shows the relationship between the log odds ratio of death/clinical failure with combination therapy and the mortality/clinical failure rate in the reference (monotherapy) group for all eligible datasets. Closed circles represent nonrandomized observational datasets ( $n = 44$ ), whereas open inverted triangles represent randomized, controlled study datasets ( $n = 12$ ). The size of the symbols is inversely proportional to the variance of each dataset. The negative slope of the regression line indicates a significant positive relationship between the probability of benefit of combination therapy and increasing risk of death/clinical failure in the reference (monotherapy) group (odds ratio, 1.304; 95% confidence interval, 1.205–1.412;  $p < .0001$  per 10% increase in reference group mortality). Combination therapy appears to hold a significant advantage at reference group mortality/clinical failure rates of  $>25\%$  (as indicated by the crossing of the upper 95% confidence interval line through a log odds ratio value of 1). However, combination therapy appears to confer a significant disadvantage at reference group mortality rates of  $\leq 15\%$ .

ogeneity or beneficial effect of combination therapy (Table 2).


## Meta-Regression

Figure 4 plots the OR of death with combination therapy (y-axis) against the mortality/clinical failure rate with monotherapy in individual datasets (x-axis). There is a significant negative slope (OR, 1.304; 95% CI, 1.205–1.412;  $p < .0001$  per 10% increase in reference group mortality), suggesting that the probability of a beneficial effect with combination therapy increases with increasing risk of death/clinical failure in the monotherapy arm. A random-effects meta-regression (OR, 1.318; 95% CI, 1.190–1.460;  $p < .0001$  per 10% increase in monotherapy group mortality) and meta-regression using the aggregate mortality of the complete datasets (i.e., both monotherapy and combination therapy groups together) in place of the monotherapy group mortality as the independent variable (OR, 1.173; 95% CI, 1.070–1.285;  $p < .0001$  per 10% increase in aggregate mortality) performed to address the issue of regression to the mean yielded similar results (21, 82, 83).

In Figure 4, the intersection of the 95% CI lines with the x-axis shows a statistically significant benefit with combination therapy begins as monotherapy mortality rate exceeds 25% (OR at 26%, 0.881; CI, 0.780–0.994;  $p = .0447$ ). In contrast, monotherapy is statistically favored at a monotherapy mortality risk of 15% or lower (OR at 15%, 1.180; CI, 1.017–1.3681;  $p = .0334$ ).

A similar trend is seen if the meta-regression is restricted to either observational studies (Fig. 5A) or RCTs (Fig. 5B).





**Figure 5.** Meta-regression of non-randomized control trial (non-RCT) (A) and RCT datasets (B). The weighted meta-regression line (with 95% confidence interval) shows the relationship between the log odds ratio of death/clinical failure with combination therapy and the mortality/clinical failure rate in the reference (monotherapy) group for each group of datasets. Closed circles represent nonrandomized observational datasets ( $n = 44$ ), whereas open inverted triangles represent randomized, controlled study datasets ( $n = 12$ ). The size of the symbols is inversely proportional to the variance of each dataset. Both datasets show a similar negative slope indicating a significant positive relationship between the probability of benefit of combination therapy and increasing risk of death/clinical failure in the reference (monotherapy) group. For the non-RCT datasets, the negative slope of the regression line indicates an odds ratio of 1.475 (95% confidence interval, 1.385–1.569;  $p < .0001$  per 10% increase in reference group mortality). Based on the 95% confidence interval, mortality/clinical failure rates in the reference group of  $>26\%$  or  $<15\%$  indicated significant benefit or harm respectively from combination therapy. For the RCT datasets, the regression line indicates an odds ratio of 1.425 (95% confidence interval, 1.121–1.811;  $p < .0001$  per 10% increase in reference group mortality). Mortality/clinical failure rates of  $\geq 35\%$  suggested significant benefit with combination therapy, but a trend toward harm at lower risk levels did not reach significance.

In addition, Table 2 contains a series of meta-regressions for subgroups. In almost every case, there is at least a trend suggesting increasing benefit with combination antimicrobial therapy as the monotherapy mortality rate increases. This effect holds whether hospital mortality, 7- to 30-day mortality, or clinical failure is used as the study end point. Further, Table 3 shows the OR intercepts at 0% and 100% mortality in the monotherapy reference group for each subgroup. Notably, whenever there is a significant meta-regression slope in Table 2, the intercept for 0% and 100% reference group mortality is always more than one and less than one, respectively. This indicates a trend toward harm and benefit, respectively, at low and high mortality risk in each subgroup (even if the range

of the 95% CI included 1.0 in some cases).

These analyses indicate that a substantial amount of heterogeneity in the OR of death/clinical failure with combination therapy is accounted for by the mortality rate of the monotherapy group. Addition of variables for other potential sources of heterogeneity and the interaction between these and monotherapy mortality rate were uniformly found to be nonsignificant ( $p > .20$ ). These other variables included, most notably, the presence or absence of an RCT study design. In addition, Gram stain character, bacteremia, pulmonary site of infection,  $>10\%$  patients with neutropenia, microbiological proof of antibiotic sensitivity, use of  $\beta$ -lactam as primary therapy, and use of aminoglycoside as secondary therapy

were also not significant in the model. Inclusion in the meta-regression of year of publication and use of mortality vs. clinical failure end point yielded similar negative results. Only monotherapy mortality rate was associated with probability of benefit with combination therapy in these analyses.

## DISCUSSION

Our results indicate, in contrast to previous meta-analytic studies (7, 8), that combination anti-infective therapy reduces mortality in patients with serious bacterial infections, but only in those at the highest risk for death (Fig. 2). The analysis of those studies that could be split into septic shock and nonshock strata (27, 28, 34, 42, 46, 54–56) suggests that the beneficial effect may be entirely restricted to septic shock cases (Fig. 3).

Our conclusions regarding the importance of mortality risk in relation to the potential benefit of combination therapy is strongly supported by the meta-regression results (Fig. 4, Table 2). The data clearly suggest that there is a statistically significant benefit of combination therapy at mortality/clinical failure risk of  $>25\%$ , but that this benefit disappears in the 15% to 25% risk range. In fact, combination therapy appears to be associated with worse survival if the reference (monotherapy) risk is 15% or less. The meta-regression also confirms that no assessed factor other than monotherapy mortality risk makes a statistically significant contribution to the model. Notably, our meta-regression results held individually in both RCT and non-RCT subgroups (Fig. 5, Table 2).

Several potential explanations for a differential impact of combination and monotherapy at varying mortality risks exist. The underlying hypothesis driving this analysis was that the evolution of septic shock is based, in part, on an increasing microbial burden relative to less severe illness (84, 85) and that persistence of shock results in a marked time-dependent increased risk of death (86, 87). Accelerated pathogen clearance in septic shock should presumably result in more rapid establishment of hemodynamic stability and improved survival. Combination therapy, particularly with  $\beta$ -lactams in combination with aminoglycosides (88–91), fluoroquinolones (92–98), and macrolides (99–102), has demonstrated evidence of synergism (i.e., accelerated pathogen clearance) in exper-

Table 3. Stratified odds ratio intercept values for 0% and 100% projected mortality

Stratification	Number of Datasets (Meta-Regression)	Meta-Regression Odds Ratio (95% Confidence Interval) Intercept at 0% Mortality	0% Mortality Intercept <i>P</i>	Meta-Regression Odds Ratio (95% Confidence Interval) Intercept at 100% Mortality	100% Mortality Intercept <i>P</i>
All datasets	56	1.710 (1.358–2.155)	<.0001	0.124 (0.068–0.225)	<.0001
Large datasets <sup>a</sup>	35	1.913 (1.448–2.528)	<.0001	0.058 (0.025–0.134)	<.0001
All split pair datasets	24	1.169 (0.796–1.717)	.4339	0.217 (0.107–0.440)	.0003
Nonsplit pair datasets	32	2.955 (2.121–4.117)	<.0001	0.026 (0.011–0.057)	<.0001
Randomized controlled trials	12	2.911(1.578–5.371)	.0066	0.020 (0.004–0.118)	.0016
Non-randomized controlled trials (observational studies)	44	2.318 (1.844–2.914)	<.0001	0.085 (0.051–0.141)	<.0001
Prospective observational studies	15	1.325 (1.001–1.755)	.0498	0.108 (0.046–0.250)	.0002
Retrospective cohort studies	29	1.927 (1.351–2.748)	.0012	0.107 (0.038–0.303)	.0002
Clinical failure end point	9	1.911 (1.026–3.557)	.0482	0.072 (0.020–0.258)	.005
Hospital mortality end point	20	2.335 (1.496–3.644)	.0015	0.071 (0.028–0.185)	<.0001
7- to 30-day mortality end point	27	1.042 (0.747–1.454)	.8110	0.098 (0.040–0.244)	<.0001
Proven microbiological sensitivity	39	1.447 (1.083–1.934)	.0170	0.179 (0.103–0.310)	<.0001
Inferred microbiological sensitivity	17	2.057 (1.329–3.183)	.0055	0.047 (0.014–0.163)	.0002
During or after 1993	33	1.340 (1.011–1.777)	.0405	0.151 (0.059–0.383)	.0008
During or before 1992	23	2.078 (1.389–3.110)	.0019	0.075 (0.033–0.169)	<.0001
Neutropenia in ≤10% of cases	20	1.939 (1.264–2.976)	.0072	0.067 (0.017–0.256)	.0009
Neutropenia in >10% of cases	11	1.497 (0.867–2.585)	.1815	0.102 (0.047–0.221)	.0003
β-lactam only as primary Rx	28	1.449 (1.024–2.051)	.0460	0.151 (0.059–0.383)	.0005
Mixed agents as primary Rx <sup>b</sup>	28	1.481 (1.125–1.949)	.0095	0.075 (0.041–0.136)	<.0001
AG excluded as primary Rx	48	1.944 (1.507–2.508)	<.0001	0.066 (0.033–0.134)	<.0001
AG only as secondary Rx	24	2.424 (1.713–3.429)	<.0001	0.060 (0.023–0.152)	<.0001
NonAG as secondary Rx <sup>c</sup>	32	1.470 (1.138–1.899)	.0061	0.140 (0.076–0.261)	<.0001
Macrolides only as secondary Rx	6	0.840 (0.509–1.387)	.5330	0.404 (0.071–2.296)	.3646
Mixed agents as secondary Rx <sup>d</sup>	24	1.800 (1.293–2.506)	.0019	0.142 (0.073–0.275)	<.0001
Bacteremia	37	1.750 (1.304–2.348)	0.0007	0.115 (0.055–0.242)	<.0001
Nonbacteremia	19	1.070 (0.734–1.561)	.7277	0.278 (0.112–0.694)	.0139
Community-acquired pneumonia	10	1.474 (1.042–2.086)	.0419	0.225 (0.073–0.693)	.0317
Hospital-acquired pneumonia/ventilator-assisted pneumonia	7	2.842 (1.397–5.784)	.0345	0.062 (0.013–0.290)	.0324
All pneumonia	17	1.477 (1.065–2.047)	.0336	0.121 (0.042–0.345)	.0013
Gram-negative infection	31	1.239 (1.186–1.294)	.0221	0.100 (0.052–0.192)	<.0001
Pseudomonas infection	11	3.014 (2.941–3.088)	.0124	0.133 (0.060–0.294)	.0008
Klebsiella infection	5	1.454 (0.554–3.819)	.4927	0.052 (0.012–0.232)	.0304
Gram-positive infection	17	1.505 (1.377–1.644)	.0451	0.175 (0.046–0.667)	.0221
Pneumococcal infection	12	0.866 (0.258–2.903)	.6171	0.135 (0.024–0.774)	.0484
Unmodified datasets	27	2.251 (2.251–2.252)	.0001	0.092 (0.040–0.213)	<.0001
Modified datasets	29	1.217 (0.919–1.613)	.1825	0.153 (0.085–0.274)	<.0001

Rx, therapy; AG, aminoglycoside.

<sup>a</sup>Datasets with an  $n \leq 25$  in either monotherapy or combination therapy arm excluded; <sup>b</sup> Primary agent other than a β-lactam only (i.e., a mix of β-lactams and other antibiotics); <sup>c</sup> Secondary agent other than only aminoglycoside; <sup>d</sup> Secondary agents not specifically defined (may include aminoglycosides, fluoroquinolones, macrolides, or others).

imental studies. Given the larger proportion of septic shock cases likely to exist in the high-risk mortality groups, any benefit of combination therapy would be ex-

pected to be disproportionately high in such groups.

Immunomodulatory effects of the supplemental agent could also provide a

greater benefit to sicker patients in view of the greater inflammatory responses seen in septic shock patients (103, 104). Potentially salutary immunomodulatory

activity has been suggested with macrolides (105–109) but has also been described with fluoroquinolones (106, 110, 111). Despite this, clinically relevant immunomodulatory activity of the secondary agent would seem to be less likely because beneficial effects would not be expected to be seen with several different antibiotic groups, particularly aminoglycosides.

The design of this study removes the potential benefit of providing a broader range of coverage for microbial pathogens with combination therapy by excluding or eliminating culture-negative cases (when possible) and retaining only studies with inferred or confirmed pathogen sensitivity to utilized antimicrobials. Notably, restriction of the dataset to studies with confirmed microbiological sensitivity (Table 2) showed the same variation in impact of combination therapy with mortality risk as the overall group.

The mechanism underlying the apparent survival disadvantage in lower-risk patients treated with combination therapy is unknown. Drug toxicity (13, 110) would seem to be most likely, but possible antibiotic antagonism (112) and the development of resistant organisms (113) could each play a role.

Because the individual studies encompassed in our study are substantially identical to those in earlier meta-analyses indicating an absence of any benefit of combination therapy (7, 8), the reason for the divergent conclusions must be addressed. The basis of the divergence appears to be differences in handling of the individual datasets. Previous meta-analytic investigations have attempted to minimize heterogeneity by focusing on specific clinical syndromes, organism groups, and study designs. We opted to maximize our sample size by including a wide variety of organisms, clinical syndromes, and types of studies. However, heterogeneity was limited by excluding most noninferiority studies because of their intrinsic structural bias toward regimen equivalence. In addition, when possible, datasets were modified to focus on  $\beta$ -lactam and/or fluoroquinolone monotherapy in comparison to a similar regimen supplemented with the addition of a secondary agent (aminoglycoside, fluoroquinolones, or macrolides). To further minimize heterogeneity, we extracted or excluded culture-negative and neutropenic cases when that was an option. Perhaps most importantly, we were able to split 12 of the study datasets into mutu-

ally exclusive shock/critically ill and non-shock/noncritically ill components. This had the effect of increasing the potential underlying signal. The result of these maneuvers was apparent in the monotherapy mortality stratified meta-analysis in which the benefit of combination antibiotic therapy is shown to be highly dependent on baseline (monotherapy) mortality risk and in the split studies that demonstrate that combination therapy benefits those groups of patients with septic shock or critical illness based on severity scoring.

Our analysis has significant limitations. Few of the included studies were randomized trials; most studies were observational, using a variety of anti-infectives for varying durations in non-standardized schedules. In these observational studies, the effect of unidentified confounding factors or residual confounding for known factors cannot be ruled out. Note that although we attempted to use an alternate indicator of severity of illness in the analysis in place of monotherapy mortality, most studies did not stratify outcome by severity of illness. This may be important because combination therapy may more likely to be administered in either the sickest patients who are more likely to die or, alternately, less likely to be administered to such patients because of concurrent organ failure, which may increase risk of drug toxicity. For example, Paul et al (78) have demonstrated that an apparent advantage of combination therapy ( $\beta$ -lactam with or without macrolides) in unadjusted data for hospitalized community-acquired pneumonia is eliminated in a propensity-adjusted analysis. The inability to adjust for confounding covariates in most of the nonrandomized cohort studies precludes drawing strong conclusions regarding our findings. However, the fact that meta-regression results held in the RCT subset of studies (Table 2) supports the validity of the central observation across the entire study dataset.

In conclusion, our study suggests that a survival benefit of combination antibiotic therapy in serious bacterial infections associated with sepsis is restricted to the most severely ill subset of patients with septic shock and/or a projected mortality/clinical failure rate of  $>25\%$  (in the absence of combination therapy). Notably, our data also suggest the possibility that combination therapy may be associated with increased risk of death in pa-

tients with low mortality risk ( $\leq 15\%$ ). The presence of septic shock may be a simple prospective method to identify patients who may benefit from combination therapy. Alternately, severity of illness scoring systems could be used to identify patients most likely to benefit. At the conclusion of this CME activity, participants should be able to select appropriate antibiotic regimens for patients with sepsis.

## ACKNOWLEDGMENTS

We thank Eric Chamot, Christian van Delden, Daren Heyland, Victor Yu, and Stephan Harbarth for providing modified datasets for analysis.

## REFERENCES

1. Darras-Joly C, Bedos JP, Sauve C, et al: Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of *Streptococcus pneumoniae* in a mouse pneumonia model. *Antimicrob Agents Chemother* 1996; 40:2147–2151
2. Calandra T, Glauser MP: Immunocompromised animal models for the study of antibiotic combinations. *Am J Med* 80:45–52, 1986
3. Kumar A, Mensing J, Zelenitsky S, et al: Effect of antibiotic sequence on blood bacterial counts in a rat model of *E. coli* peritonitis/septic shock. *IAAC Proc* 2004; 26: A-1296
4. Anderson ET, Young LS, Hewitt WL: Antimicrobial synergism in the therapy of gram-negative rod bacteremia. *Chemotherapy* 1978; 24:45–54
5. De Jongh CA, Joshi JH, Newman KA, et al: Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. *Am J Med* 1986; 80:96–100
6. Bouza E, Munoz P: Monotherapy versus combination therapy for bacterial infections. *Med Clin North Am* 2000; 84: 1357–1389
7. Safdar N, Handelsman J, Maki DG, et al: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. *Lancet Infect Dis* 2004; 4:519–527
8. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. *BMJ* 2004; 328: 668–679
9. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. *Am J Respir Crit Care Med* 2002; 166:1197–1205
10. Boissel JP, Collet JP, Lievre M, et al: An



- effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients. *J Cardiovasc Pharmacol* 1993; 22:356–363
11. Antman EM, Seelig MS, Fleischmann K, et al: Magnesium in acute myocardial infarction: Scientific, statistical, and economic rationale for its use. *Cardiovasc Drugs Ther* 1996; 10:297–301
12. Schmid CH, Lau J, McIntosh MW, et al: An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. *Stat Med* 1998; 17:1923–1942
13. Vidal L, Gafter-Gvili A, Borok S, Fraser A, et al: Efficacy and safety of aminoglycoside monotherapy: Systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2007; 60:247–257
14. Crabtree TD, Pelletier SJ, Gleason TG, et al: Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients. *Arch Surg* 1999; 134: 1293–1298
15. DerSimonian R: Meta-analysis in the design and monitoring of clinical trials. *Stat Med* 1996; 15:1237–1248
16. Valles J, Rello J, Ochagavia A, et al: Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. *Chest* 2003; 123:1615–1624
17. Brun-Buisson C, Meshaka P, Pinton P, et al: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med* 2004; 30:580–588
18. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003; 348:1546–1554
19. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. *BMJ* 2003; 327:557–560
20. Egger M, Davey SG, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315:629–634
21. Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002; 21: 1559–1573
22. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-analysis: multivariate approach and meta-regression. *Stat Med* 2002; 21:589–624
23. Sculier JP, Coppens L, Klastersky J: Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia. *J Antimicrob Chemother* 1982; 9:63–68
24. Karnad A, Alvarez S, Berk SL: Pneumonia caused by gram-negative bacilli. *Am J Med* 1985; 79:61–67
25. Vazquez EG, Mensa J, Martinez JA, et al: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. *Eur J Clin Microbiol Infect Dis* 2005; 24:190–195
26. Dwyer R, Ortqvist A, Aufwerber E, et al: Addition of a macrolide to a  $\beta$ -lactam in bacteremic pneumococcal pneumonia. *Eur J Clin Microbiol Infect Dis* 2006; 25: 518–521
27. Baddour LM, Yu VL, Klugman KP, et al: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. *Am J Respir Crit Care Med* 2004; 170:440–444
28. Rodriguez A, Mendia A, Sirvent JM, et al: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. *Crit Care Med* 2007; 35:1493–1498
29. Chow JW, Fine MJ, Shlaes DM, et al: Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. *Ann Intern Med* 1991; 115:585–590
30. Kim BN, Lee SO, Choi SH, et al: Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: An analysis of 249 cases caused by *Citrobacter*, *Enterobacter*, and *Serratia* species. *Int J Antimicrob Agents* 2003; 22:106–111
31. Chokshi R, Restrepo MI, Weeratunge N, et al: Monotherapy versus combination antibiotic therapy for patients with bacteremic *Streptococcus pneumoniae* community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 2007; 26:447–451
32. Martinez JA, Horcajada JP, Almela M, et al: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2003; 36: 389–395
33. Damas P, Garweg C, Monchi M, et al: Combination therapy versus monotherapy: A randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. *Crit Care* 2006; 10:R52
34. Korvick JA, Bryan CS, Farber B, et al: Prospective observational study of *Klebsiella* bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. *Antimicrob Agents Chemother* 1992; 36:2639–2644
35. Cometta A, Baumgartner JD, Lew D, et al: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. *Antimicrob Agents Chemother* 1994; 38: 1309–1313
36. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. *Am J Med* 1980; 68:344–355
37. McCue JD: Improved mortality in gram-negative bacillary bacteremia. *Arch Intern Med* 1985; 145:1212–1216
38. Bouza E, Garcia DLT, Erice A, et al: *Serratia* bacteremia. *Diagnos Microbiol Infect Dis* 1987; 7:237–247
39. Carbon C, Auboyer C, Becq-Giraudon B, et al: Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: A multicenter study. *Chemioterapia* 1987; 6(2 Suppl):367–68
40. McCue JD: Gram-negative bacillary bacteremia in the elderly: Incidence, ecology, etiology, and mortality. *J Am Geriatr Soc* 1987; 35:213–218
41. Kuikka A, Sivenon A, Emelianova A, et al: Prognostic factors associated with improved outcome of *Escherichia coli* bacteremia in a Finnish university hospital. *Eur J Clin Microbiol Infect Dis* 1997; 16:125–134
42. Harbarth S, Garbino J, Pugin J, et al: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. *Eur J Clin Microbiol Infect Dis* 2005; 24:688–690
43. Siegman-Igra Y, Ravona R, Primerman H, et al: *Pseudomonas aeruginosa* bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. *Int J Infect Dis* 1998; 2:211–215
44. Gullberg RM, Homann SR, Phair JP: Enterococcal bacteremia: Analysis of 75 episodes. *Rev Infect Dis* 1989; 11:74–85
45. Leibovici L, Paul M, Poznanski O, et al: Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study. *Antimicrob Agents Chemother* 1997; 41:1127–1133
46. Heyland DK, Dodek P, Muscedere J, et al: Randomized trial of monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. *Crit Care Med* 2008; 36:737–744
47. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. *Arch Intern Med* 2001; 161:1837–1842
48. Dupont H, Carbon C, Carlet J: Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial The Severe Generalized Peritonitis Study Group. *Antimicrob Agents Chemother* 2000; 44:2028–2033
49. Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for *Klebsiella pneumoniae* bacteremia: Implications of production of extended-spectrum beta-lactamases. *Clin Infect Dis* 2004; 39:31–37
50. Kim BN, Ryu J, Kim YS, et al: Retrospective analysis of clinical and microbiological aspects of *Klebsiella oxytoca* bacteremia over a 10-year period. *Eur J Clin Microbiol Infect Dis* 2002; 21:419–426
51. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A, et al: Nosocomial pneumonia: Comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. *Infection* 1991; 19(Suppl 6):S320–S325



52. Kuikka A, Valtonen VV: Factors associated with improved outcome of *Pseudomonas aeruginosa* bacteremia in a Finnish university hospital. *Eur J Clin Microbiol Infect Dis* 1998; 17:701–708
53. Piccart M, Klastersky J, Meunier F, et al: Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. *Antimicrob Agents Chemother* 1984; 26:870–875
54. Bodey GP, Jadeja L, Elting L: *Pseudomonas* bacteremia. Retrospective analysis of 410 episodes. *Arch Intern Med* 1985; 145: 1621–1629
55. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al: Optimal management therapy for *Pseudomonas aeruginosa* ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. *Crit Care Med* 2007; 35:1888–1895
56. Chamot E, Boffi EA, Rohner P, et al: Effectiveness of combination antimicrobial therapy for *Pseudomonas aeruginosa* bacteremia. *Antimicrob Agents Chemother* 2003; 47:2756–2764
57. Kljucar S, Heimesaat M, von Pritzbuer E, et al: Ceftazidim mit und ohn tobramycin versus azlocillin plus tobramycin in der therapie bronchopulmonaler infektionen bei intensivpatienten. *Infection* 1987; 15: S185–S191
58. Kljucar S, Heimesaat M, van Pritzbuer E, et al: Comparative clinical trial with ceftazidime (CAZ) versus Ceftazidime plus tobramycin (TOB) versus azlocillin (AZL) plus tobramycin in ventilated patients with nosocomial lower respiratory tract infection (LRTI). Proceedings of the 30th International Conference on Antimicrobial Agents and Chemotherapy. 1990; 953
59. D'Antonio D, Fioritoni G, Iacone A, et al: Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empiric treatment of infections in patients with altered host defense: Microbiological and clinical evaluation. *Chemotherapy* 1992; 28:420–427
60. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: Outcome correlations in a prospective study of 200 patients. *Am J Med* 1989; 87:540–546
61. Watanakunakorn C, Patel R: Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin. *Clin Infect Dis* 1993; 17:74–78
62. Klastersky J, Cappel R, Daneau D: Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. *Cancer* 1973; 31:331–336
63. Montgomerie JZ, Ota JK: Klebsiella bacteremia. *Arch Intern Med* 1980; 140:525–527
64. Graninger W, Ragette R: Nosocomial bacteremia due to *Enterococcus faecalis* without endocarditis. *Clin Infect Dis* 1992; 15:49–57
65. Ko WC, Lee HC, Chuang YC, et al: Clinical features and therapeutic implications of 104 episodes of monomicrobial *Aeromonas* bacteremia. *J Infect* 2000; 40:267–273
66. Aspa J, Rajas O, Rodriguez DC, et al: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. *Eur Respir J* 2006; 27:1010–1019
67. Fainstein V, Bodey GP, Elting L, et al: A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. *J Antimicrob Chemother* 1983; 12(Suppl 10): 101–10
68. Maki DG, Agger WA: Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management. *Medicine* 1988; 67: 248–269
69. Mendelson MH, Gurtman A, Szabo S, et al: *Pseudomonas aeruginosa* bacteremia in patients with AIDS. *Clin Infect Dis* 1994; 18: 886–895
70. Bodey GP, Elting LS, Rodriguez S, H et al: Klebsiella bacteremia: A 10-year review in a cancer institution. *Cancer* 1989; 64: 2368–2376
71. Feldman C, Smith C, Levy H, et al: Klebsiella pneumoniae bacteremia at an urban general hospital. *J Infect* 1990; 20:21–31
72. Tapper ML, Armstrong D: Bacteremia due to *Pseudomonas aeruginosa* complicating neoplastic disease: A progress report. *J Infect Dis* 1974; 130:S14–S23
73. Hammond JM, Potgieter PD, Linton DM, et al: Intensive care management of community-acquired Klebsiella pneumonia. *Respir Med* 1991; 85:11–16
74. de la Torre G, Romero-Vivas J, Martinez-Beltran J, et al: Klebsiella bacteremia: An analysis of 100 episodes. *Rev Infect Dis* 1985; 7:143–150
75. Fowler RA, Flavin KE, Barr J, et al: Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. *Chest* 2003; 123:835–844, 2003
76. Gleason PP, Meehan TP, Fine JM, et al: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. *Arch Intern Med* 1999; 159:2562–2572
77. Dudas V, Hopefl A, Jacobs R, et al: Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals. *Ann Pharmacother* 2000; 34:446–452
78. Paul M, Nielsen AD, Gafter-Gvili A, et al: The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. *Eur Respir J* 2007; 30:525–531
79. Krumpe PE, Cohn S, Garreltes J, et al: Intravenous and oral mono- or combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy Ciprofloxacin Study Group. *J Antimicrob Chemother* 1999; 43(Suppl A):117–28
80. Weiss K, Low DE, Cortes L, et al: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic *Streptococcus pneumoniae* pneumonia in adults. *Can Respir J* 2004; 11:589–593
81. Korvick JA, Peacock JE Jr, Muder RR, et al: Addition of rifampin to combination antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: Prospective trial using the Zelen protocol. *Antimicrobial Agents Chemother* 1992; 36:620–625
82. Higgins JP, Thompson SG: Controlling the risk of spurious findings from meta-regression. *Stat Med* 2004; 23:1663–1682
83. Thompson SG, Smith TC, Sharp SJ: Investigating underlying risk as a source of heterogeneity in meta-analysis. *Stat Med* 1997; 16:2741–2758
84. Rello J, Lisboa T, Lujan M, et al: Severity of pneumococcal pneumonia associated with genomic bacterial load. *Chest* 2009; 136: 832–840
85. Ovstebo R, Brandtzaeg P, Brusletto B, et al: Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of *Neisseria meningitidis* DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. *J Clin Microbiol* 2004; 42:2980–2987
86. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; 34: 1589–1596
87. Kumar A, Haery C, Paladugu B, et al: The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of *Escherichia coli* septic shock: Association with serum lactate and inflammatory cytokine levels. *J Infect Dis* 2006; 193:251–258
88. Comber KR, Basker MJ, Osborne CD, et al: Synergy between ticarcillin and tobramycin against *Pseudomonas aeruginosa* and Enterobacteriaceae in vitro and in vivo. *Antimicrob Agents Chemother* 1977; 11: 956–964
89. Archer G, Fekety FR Jr: Experimental endocarditis due to *Pseudomonas aeruginosa* II. Therapy with carbenicillin and gentamicin. *J Infect Dis* 1977; 136:327–335
90. Yoshikawa TT, Shibata SA: In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1978; 13:997–999
91. Kluge RM, Standiford HC, Tatem B, et al: Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against *Pseudomonas aeruginosa*. *Antimicrobial Agents Chemother* 1974; 6:442–446
92. Gimeno C, Borja J, Navarro D, et al: In vitro

- interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. *Chemotherapy* 1998; 44:94–98
93. Gradeliski E, Kolek B, Bonner DP, et al: Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. *Int J Antimicrob Agents* 2001; 17: 103–107
  94. Zembower TR, Noskin GA, Postelnick MJ, et al: The utility of aminoglycosides in an era of emerging drug resistance. *Int J Antimicrob Agents* 1998; 10:95–105
  95. Neu HC: Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. *Drugs* 1993; 45(Suppl-3):54–8
  96. Pohlman JK, Knapp CC, Ludwig MD, et al: Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. *Diagn Microbiol Infect Dis* 1996; 26:29–33
  97. Milatovic D, Wallrauch C: In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. *Eur J Clin Microbiol Infect Dis* 1996; 15: 688–693
  98. Pankuch GA, Lin G, Seifert H, et al: Activity of meropenem with and without ciprofloxacin and colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2008; 52: 333–336
  99. MacGowan AR, Bowker K, Bedford KA, et al: Synergy testing of macrolide combinations using the checkerboard technique. *J Antimicrob Chemother* 1993; 32:913–915
  100. Furuya R, Nakayama H, Kanayama A, et al: In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of *Neisseria gonorrhoeae*. *J Infect Chemother* 2006; 12: 172–176
  101. Maioli E, Debbia EA, Gualco L, et al: In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and *Pseudomonas aeruginosa*. *New Microbiol* 2008; 31: 37–46
  102. Allen NE, Epp JK: Mechanism of penicillin-erythromycin synergy on antibiotic-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1978; 13:849–853
  103. Gogos CA, Drosou E, Bassaris HP, et al: Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. *J Infect Dis* 2000; 181:176–180
  104. Oberholzer A, Souza SM, Tschoeke SK, et al: Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. *Shock* 2005; 23:488–493
  105. Guchelaar HJ, Schultz MJ, van D, et al: Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. *Fund Clin Pharmacol* 2001; 15:419–424
  106. Labro MT: Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales”? *Clin Micro Rev* 2000; 13:615–650
  107. Labro MT: Cellular and molecular effects of macrolides on leukocyte function. *Curr Pharma Design* 2004; 10:3067–3080
  108. Khan AA, Slifer TR, Araujo FG, et al: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. *Int J Antimicrob Agents* 1999; 11:121–132
  109. Oda H, Kadota J, Kohno S, et al: Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. *Chest* 1994; 106:1116–1123
  110. Pasquale TR, Tan JS: Nonantimicrobial effects of antibacterial agents. *Clin Infect Dis* 2005; 40:127–135
  111. Khan AA, Slifer TR, Remington JS: Effect of trovafloxacin on production of cytokines by human monocytes. *Antimicrob Agents Chemother* 1998; 42:1713–1717
  112. Acar JF: Antibiotic synergy and antagonism. *Med Clin North Am* 2000; 84:1391–1406
  113. Tillotson JR, Finland M: Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. *J Infect Dis* 1969; 119:597–624